Delivery of antituberculosis drugs to Mycobacterium tuberculosis H37Rv infected macrophages via polylactide-co-glycolide (PLGA) nanoparticles

Abstract

In the course of 5 decades, tuberculosis stays at its most elevated peak in the event of mortal cases revealed. This manuscript is given with an aim to update the information on tuberculosis, its pathogenesis and antitubercular chemotherapies which have been being used to prevent and cure it currently. Rising rates of tuberculosis and its high resistance toward drugs has created a need to discover better diagnostic tools and effective vaccines. This article reviews the currently available relevant publications elaborating the approach of nanoparticles futuristically in reference to diagnosis, treatment and prevention of tuberculosis. This review covers the prospect of using nanotechnology-based drug delivery systems for effective eradication of mycobacterial infections. Drug loaded polylactide-co-glycolide (PLGA) nanoparticles shows long-term stability and target only infected cells without harming the normal cells. Drug delivery using nanoparticle was previously successfully used for cancer treatment but it may also be used for treatment of tuberculosis. Transferring drug by using biodegradable nanoparticles would turn out to be a beneficial approach to stop TB epidemic.